Patent classifications
C12Y304/21038
METHODS OF ADMINISTERING INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES
The invention relates to inhibitory anti-factor XII/FXIla antibodies and methods of their use.
Nucleic acids encoding inhibitory anti-factor XII/XIIa monoclonal antibodies
The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
Methods of administering inhibitory anti-factor XII/XIIA monoclonal antibodies
The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
INHIBITORY ANTI-FACTOR XII/XIIA MONOCLONAL ANTIBODIES AND THEIR USES
The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR BINDING PEPTIDES AND METHODS OF USE
Disclosed herein, are peptides that bind urokinase-type plasminogen activator receptors. The peptides may comprise amino acid sequences of IPPWEAPK (SEQ ID NO: 1), DLAQCQTPTQAAPPTPVSPR (SEQ ID NO: 2), or LHVPLMPAQPAPPK (SEQ ID NO: 3), or retro-inverso amino acid sequences of the above enumerated sequences. Also described herein, are methods of administering compounds comprising peptides that bind urokinase-type plasminogen activator receptors to subjects for the treatment of ovarian cancer and improving wound closure.
Assays for determining plasma kallikrein system biomarkers
Methods and assays for determining the activation level of the plasma kallikrein (pKal) system and the uses thereof for assessing the activity of pKal modulators on the pKal system.